$14.79 +0.13 (%) Keryx Biopharmaceuticals - NASDAQ

Dec. 19, 2014 | 03:59 PM

Partner Headlines

  1. Seth Klarman Keeps Buying LNG, KERX, PBF And Keeps Selling THRX

    GuruFocus | Dec. 5, 2014 | 10:47AM EST
  2. Keryx Reports Issuance of New US Patent for Auryxia(TM) Covering Orally Administrable

    Benzinga | Dec. 4, 2014 | 07:33AM EST
  3. Keryx Offers Phase 2 Trial Results for Auryxia in NDD-CKD Patients

    Benzinga | Dec. 2, 2014 | 07:33AM EST
  4. Auryxia Phase 2 Data Published In The American Journal Of Kidney Disease

    Benzinga | Dec. 2, 2014 | 07:30AM EST
  5. Mid-Day Market Update: SunEdison, TerraForm Jump On First Wind Acquisition; TJX Shares Drop

    Benzinga | Nov. 18, 2014 | 13:17PM EST
  6. Events for the Week of Nov. 17-21, 2014

    Benzinga | Nov. 17, 2014 | 13:13PM EST
  7. Baupost's Seth Klarman Buys Cheniere Energy, Ocwen Financial, Antero Resources, Sells Boyd ...

    GuruFocus | Nov. 14, 2014 | 18:08PM EST
  8. Infoblox Inc Gains On Upbeat Results; The Gap Inc. Shares Decline

    Benzinga | Sep. 5, 2014 | 12:36PM EST
  9. Seth Klarman's The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, ...

    GuruFocus | Aug. 14, 2014 | 19:02PM EST
  10. H.C. Wainwright & Co. Believes Keryx Biopharmaceuticals Remains Undervalued

    Benzinga | Aug. 8, 2014 | 09:24AM EST
  11. UPDATE: Keryx Announces Zerenex LT Phase 3 Results Shows 'Highly Statistically Significant' Change, Met Primary Endpoint

    Benzinga | Jul. 24, 2014 | 17:04PM EST
  12. Seth Klarman Tops Guru Scoreboard for First Half 2014

    GuruFocus | Jul. 5, 2014 | 16:52PM EST
  13. Seth Klarman Is Top-Performing Guru for First Half 2014

    GuruFocus | Jul. 5, 2014 | 16:52PM EST
  14. Morning Market Movers

    Benzinga | Jun. 24, 2014 | 09:40AM EST
  15. Baupost's Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals

    GuruFocus | May. 12, 2014 | 18:43PM EST
  16. UPDATE: MLV & Co Reiterates On Keryx Biopharmaceuticals On Increased Risk

    Benzinga | May. 12, 2014 | 08:12AM EST
  17. Keryx Biopharma Reports Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting

    Benzinga | Apr. 9, 2014 | 08:33AM EST
  18. Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex

    Benzinga | Apr. 2, 2014 | 08:32AM EST
  19. Mid-Afternoon Market Update: Markets Turn Red as Dish Network Rises

    Benzinga | Mar. 26, 2014 | 15:46PM EST
  20. Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline

    Benzinga | Mar. 26, 2014 | 12:28PM EST
  21. Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD

    GuruFocus | Mar. 24, 2014 | 12:06PM EST
  22. Kiplinger's Tom Petruno Breaks Down The Best Bull Market Stocks

    Benzinga | Mar. 19, 2014 | 13:31PM EST
  23. Keryx Prices 6.9M Share Offering at $14.50/Share

    Benzinga | Jan. 22, 2014 | 22:54PM EST
  24. Keryx UPDATE: Biopharmaceuticals Announces $90M Proposed Public Offering of Common Stock

    Benzinga | Jan. 21, 2014 | 16:23PM EST
  25. Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ

    GuruFocus | Jan. 6, 2014 | 18:26PM EST
  26. Top Stocks Of 2013 Run Gamut: Solar, Drugs, Tech, TV

    IBD | Jan. 2, 2014 | 18:59PM EST
  27. UPDATE: J.P. Morgan Reiterates on Keryx Biopharmaceuticals on Model Update After Positive NDD-CKD Data

    Benzinga | Nov. 7, 2013 | 10:12AM EST
  28. Keryx Biopharmaceuticals Announces Zerenex(TM) (ferric citrate coordination complex) Meets All Primary and Key Secondary Endpoints in Phase 2 Study

    Benzinga | Nov. 5, 2013 | 07:36AM EST
  29. UPDATE: JMP Securities Reiterates on Keryx Biopharmaceuticals on Blockbuster Potential Growing for Zerenex

    Benzinga | Nov. 4, 2013 | 09:17AM EST
  30. Keryx Says FDA Accepted Filing for Zerenex NDA

    Benzinga | Oct. 8, 2013 | 08:31AM EST
  31. UPDATE: H.C. Wainwright Initiates Coverage on Keryx Biopharmaceuticals on Discounted Revenues, EPS Valuation Methodology

    Benzinga | Sep. 25, 2013 | 11:15AM EST
  32. Market Wrap for Tuesday, January 29: Dow and S&P Record Solid Gains, Nasdaq Lags

    Benzinga | Jan. 29, 2013 | 09:35AM EST
  33. UPDATE: Oppenheimer Raises PT to $11 on KERYX Biopharmaceuticals; Zerenex Study Beats Expectations

    Benzinga | Jan. 29, 2013 | 06:16AM EST
  34. Market Wrap for Monday, January 28: Dow and S&P Fall Slightly; Nasdaq Records Small Gain

    Benzinga | Jan. 28, 2013 | 09:45AM EST
  35. Morning Market Movers

    Benzinga | Jan. 28, 2013 | 02:47AM EST
  36. Keryx Biopharma Says Trial on Zerenex Met Primary, Secondary Key Endpoints

    Benzinga | Jan. 28, 2013 | 00:04AM EST
  37. Keryx Biopharmaceuticals to Discuss Top-Line Results from Zerenex Phase 3 Study

    Benzinga | Jan. 27, 2013 | 12:02PM EST
  38. Keryx Biopharmaceuticals, Inc. (KERX) CFO James F Iii Oliviero sells 10,859 Shares

    GuruFocus | Jan. 4, 2013 | 13:37PM EST
  39. Keryx Biopharmaceuticals, Inc. (KERX) CEO Ron Bentsur sells 6,010 Shares

    GuruFocus | Jan. 4, 2013 | 13:37PM EST
  40. Dawson James Securities Reiterates Market Outperform Rating, $4 PT on Keryx Biopharmaceuticals

    Benzinga | Nov. 28, 2012 | 02:54AM EST
  41. Keryx Biopharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Nov. 8, 2012 | 12:06PM EST
  42. Keryx Biopharmaceuticals Inc. (KERX) CFO James F Iii Oliviero sells 4,973 Shares

    GuruFocus | Oct. 5, 2012 | 17:00PM EST
  43. Keryx Biopharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus | Aug. 8, 2012 | 13:35PM EST
  44. Keryx Biopharmaceuticals Inc. (KERX) CFO James F Iii Oliviero sells 4,559 Shares

    GuruFocus | Jul. 6, 2012 | 15:53PM EST
  45. Lan Airlines, VimpelCom Among Stocks Down on Above-average Volume Thursday

    FoxBusiness | Jul. 5, 2012 | 06:32AM EST
  46. Benzinga's Top Upgrades with Color for May 10, 2012

    Benzinga | May. 10, 2012 | 06:02AM EST
  47. UPDATE: Ladenburg Thalmann Upgrades Keryx Biopharmaceuticals; Establishes PT

    Benzinga | May. 10, 2012 | 04:54AM EST
  48. Stock Futures Point to Weak Start for the Quarter with Avon Products (AVP) and Groupon (GRPN) on the Move

    MarketIntelligenceCenter | Apr. 2, 2012 | 08:03AM EST
  49. Morning Social Media Outlook for Tuesday Mar 6 (SHFL, HAR, PCX, NTRI)

    Benzinga | Mar. 6, 2012 | 02:54AM EST
  50. Keryx Biopharma Trade Lower after Adam Feuerstein's Negative Blog Post

    Benzinga | Mar. 6, 2012 | 00:47AM EST
Trading Center